<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333732</url>
  </required_header>
  <id_info>
    <org_study_id>202004099</org_study_id>
    <secondary_id>INV-017499</secondary_id>
    <nct_id>NCT04333732</nct_id>
  </id_info>
  <brief_title>CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION</brief_title>
  <acronym>CROWN CORONA</acronym>
  <official_title>An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>COVID -19 Therapeutics Accelerator</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of CROWN CORONATION is the prevention of symptomatic COVID-19 by using&#xD;
      combinations of approved and safe repurposed interventions, with complementary mechanisms of&#xD;
      action.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CROWN CORONATION is an international, Bayesian platform adaptive, randomized,&#xD;
      placebo-controlled trial assessing the effectiveness of candidate interventions in preventing&#xD;
      COVID-19 disease in adults.&#xD;
&#xD;
      Randomization will be stratified by age (&lt;50 and ≥50) and site. Participants will be&#xD;
      healthcare workers at risk of contracting SARS-CoV-2. Participants will be randomized into&#xD;
      one of two arms:&#xD;
&#xD;
        -  Education and surveillance plus MR or MMR vaccine&#xD;
&#xD;
        -  Education and surveillance plus Placebo&#xD;
&#xD;
      While the initial intervention to be tested on the platform will be the MR or MMR vaccine,&#xD;
      other interventions might be added or removed over the course of the trial. The trial will&#xD;
      evaluate which of the intervention arms is most effective at decreasing the incidence of&#xD;
      symptomatic COVID-19 disease, without unacceptable side effects or safety events.&#xD;
&#xD;
      All participants will require be required to have a mobile phone to participate. This is&#xD;
      standard in all the countries in this study. Most, but not all, will also have a smartphone.&#xD;
      Participants will complete weekly data logs via SMS texting. Follow-up information will be&#xD;
      collected until approximately 5 months after the end of treatment or death. Participants who&#xD;
      develop symptomatic COVID-19 during the last month of observation will at a minimum be&#xD;
      followed-up until symptom resolution and at a maximum until 6 months after randomization&#xD;
      (whichever comes first). Telemedicine approaches to collecting information on participants&#xD;
      will be used where possible. The trial will provide adherence support interventions that have&#xD;
      been shown in randomized controlled trials to improve adherence to Human Immunodeficiency&#xD;
      Virus treatment and adapted for HIV Pre-Exposure Prophylaxis (HIV PrEP) (e.g. two-way SMS&#xD;
      with check in for those that report symptoms or adverse events). The database will be hosted&#xD;
      on UK-based servers which are expected to be managed by Sealed Envelope Ltd. Local&#xD;
      investigators will have access to the part of the CRF to enable recording of outcome data&#xD;
      and/or severity of COVID-19 symptoms. Participants will be given a secure login to enable&#xD;
      them to complete an initial participant health questionnaire and the regular data logs. It is&#xD;
      envisaged that these will be completed at least weekly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An international, multi-site, randomized, placebo-controlled, Bayesian platform clinical trial. Initially there will be 2 arms, but we anticipate adding intervention arms to the platform. Combining interventions, allowing assessment of potential interactions, will be considered when arms are added.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>For the MR or MMR vaccine, there will be a placebo vaccine. Attempts will be made to maintain masking for other interventions (e.g. oral tablets) added to the platform by including suitable placebo options.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic COVID-19</measure>
    <time_frame>60 days</time_frame>
    <description>To determine the incidence of the trial intervention(s) in preventing laboratory test-confirmed, symptomatic COVID19 (i.e. any of the following: cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, or diarrhea), in healthcare workers with repeated exposures to SARS-CoV-2 by day 60 after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of COVID-19 over the study period</measure>
    <time_frame>60 days</time_frame>
    <description>Severity of COVID-19 will be graded on a simplified version of the ordinal World Health Organization COVID-19 severity scale (WHO COVID-19 severity scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of preventing/reducing SARS-CoV-2 infection</measure>
    <time_frame>5 months</time_frame>
    <description>SARS-CoV-2 infection (by serology) over up to 5 months of follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>M-M-R II ®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Education and surveillance plus M-M-R II ®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Education and surveillance plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR or M-M-R II ® vaccine</intervention_name>
    <description>Education and surveillance plus MR or M-M-R II ® vaccine</description>
    <arm_group_label>M-M-R II ®</arm_group_label>
    <other_name>Merck</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Volunteers without clinical evidence of COVID-19 infection aged 18 years and older.&#xD;
&#xD;
          2. Healthcare workers based in a primary, secondary or tertiary healthcare setting with a&#xD;
             high risk of developing COVID-19 due to their potential exposure to patients with&#xD;
             SARS-CoV-2 infection.&#xD;
&#xD;
          3. Must have a mobile phone and access to the Internet for data collection purposes.&#xD;
&#xD;
          4. Participants who are willing and able to provide informed consent via an electronic&#xD;
             consent process.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Prior enrollment into other COVID-19 interventional prevention or treatment trials&#xD;
             (observational trials not excluded).&#xD;
&#xD;
          2. Self-reported or diagnosed current infection with SARS-CoV-2 or previous COVID-19&#xD;
             diagnosis.&#xD;
&#xD;
          3. Self-reported current acute respiratory infection.&#xD;
&#xD;
          4. Concurrent and/or recent involvement in other research or use of the investigational&#xD;
             product, a product considered to be equivalent to the investigational product, or any&#xD;
             other product that is likely to interfere with the investigational products in this&#xD;
             trial used within three months of study enrolment.&#xD;
&#xD;
          5. Self-reported known allergies to any of the IMPs and excipients of the IMPs and&#xD;
             placebo.&#xD;
&#xD;
          6. Self-reported presence or history of the conditions listed in the appendices.&#xD;
&#xD;
          7. Self-reported current use of medication known to interact with any of the medications&#xD;
             listed in the appendices.&#xD;
&#xD;
          8. Inability or unwillingness to be followed up for the trial period.&#xD;
&#xD;
        For M-M-R II&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Individuals receiving high dose corticosteroids, other immuno-suppressive drugs,&#xD;
             alkylating agents or anti-metabolites.&#xD;
&#xD;
          -  Individuals undergoing radiotherapy.&#xD;
&#xD;
          -  Any malignant disease either untreated or currently undergoing therapy.&#xD;
&#xD;
          -  History of administration of gammaglobulin or blood transfusions within the previous 3&#xD;
             months.&#xD;
&#xD;
          -  Participants with an allergy to the MR (MMR) vaccine or its components, including&#xD;
             neomycin.&#xD;
&#xD;
          -  Idiopathic thrombocytopenic purpura (ITP)&#xD;
&#xD;
          -  Untreated tuberculosis&#xD;
&#xD;
          -  Prior receipt of any vaccines (licensed or investigational) ≤30 days before enrollment&#xD;
&#xD;
          -  Planned receipt of any vaccine other than the study intervention within 30 days before&#xD;
             and after the study vaccination (not including the flu vaccination via injection)&#xD;
&#xD;
          -  Prior receipt of an investigational or licensed vaccine likely to impact on&#xD;
             interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus&#xD;
             vaccines).&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient state, including&#xD;
             untreated HIV infection with a CD4T count &lt;200 /mL&#xD;
&#xD;
          -  Asplenia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S. Avidan, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Univeristy School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramani Moonesinghe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Rees, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wits University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Yun, BS, CCRP</last_name>
    <phone>314-273-2240</phone>
    <email>crowntrial@email.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherry McKinnon, MS, CCRP</last_name>
    <phone>314-286-1768</phone>
    <email>crowntrial@email.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Yun, BS, CCRP</last_name>
      <phone>314-273-2240</phone>
      <email>CrownTrial@email.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sherry McKinnon, MS, CCRP</last_name>
      <phone>314-286-1768</phone>
      <email>CrownTrial@email.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael S. Avidan, MBBCh, FCASA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Politi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Dubberke, MD, MSPH, FSHEA, FIDSA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Graham Colditz, MD, DrPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Lenz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shabaana A. Khader, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ghana Medical Centre</name>
      <address>
        <city>Accra</city>
        <state>Greater Accra Region</state>
        <zip>00233</zip>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Kyei, MD, PhD</last_name>
      <phone>+233551989937</phone>
      <email>mailto:gkyei@noguchi.ug.edu.gh</email>
    </contact>
    <contact_backup>
      <last_name>Nana Adwoa Dsane, MA</last_name>
      <phone>+233243376304</phone>
    </contact_backup>
    <investigator>
      <last_name>Kwadwo Koram, MB ChB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groote Schuur/J52, Desmond Tutu Health Foundation</name>
      <address>
        <city>Mowbray</city>
        <state>Cape Town</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doerieyah Reynolds</last_name>
      <email>Doerieyah.Reynolds@hiv-research.org.za</email>
    </contact>
    <contact_backup>
      <last_name>Margot Flint</last_name>
      <email>margot.flint@uct.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Linda-Gail Bekker, MBChB, DTM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Orrell, MBChB MMed MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Biccard, MBChB, FCA, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masiphumelele, Desmond Tutu Health Foundation</name>
      <address>
        <city>Sunnydale</city>
        <state>Cape Town</state>
        <zip>7975</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda-Gail Bekker, MBChB, DTM</last_name>
      <email>Linda-Gail.Bekker@hiv-research.org.za</email>
    </contact>
    <contact_backup>
      <last_name>Menna Duyver</last_name>
      <email>menna.duyver@hiv-research.org.za</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine Gill, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JOSHA Research</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin Turton, MBChB, Dip PEC, DA, MMed, FCA</last_name>
      <phone>+27 82 804 6839</phone>
      <email>turtonew@ufs.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Carine Pienaar</last_name>
      <email>carine.pienaar@josha.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Edwin Turton, MBChB, Dip PEC, DA, MMed, FCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wits RHI, University of the Witwatersrand</name>
      <address>
        <city>Hillbrow</city>
        <state>Johannesburg,Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sinead Delany-Moretlwe, MBChB, PhD, DTM&amp;H</last_name>
      <phone>+27 82 377 6275</phone>
      <email>sdelany@wrhi.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>mandisa Tsholwana</last_name>
      <email>mtsholwana@wrhi.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Kim Comline</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical HIV Research Unit (CHRU)</name>
      <address>
        <city>Auckland Park</city>
        <state>Johannesburg</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamoloko Mashamaite</last_name>
      <email>mmashamaite@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Thando Mwelase, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU)</name>
      <address>
        <city>Diepkloof</city>
        <state>Johannesburg</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leisha Genade</last_name>
      <email>genadel@phru.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Limakato Lebina, MBChB, MPH</last_name>
      <email>lebinal@phru.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Limakatso Lebina, MBChB, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Soshanguve</city>
        <state>Tshwane</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katlego Mapetla</last_name>
      <email>KMapetla@setshaba.org.za</email>
    </contact>
    <contact_backup>
      <last_name>Khatija Ahmed</last_name>
      <email>kahmed@setshaba.org.za</email>
    </contact_backup>
    <investigator>
      <last_name>Khatija Ahmed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Biccard, MBChB,FCA,PhD</last_name>
      <phone>+27 21 4045015</phone>
      <email>bruce.biccard@uct.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Margot Flint</last_name>
      <email>margot.flint@uct.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Biccard, MBChB,FCA,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Willem Stassen, BTech, MPhil, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Alan Wallis, MBChB, FCS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Joubert, MBChB, FCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lulu Nair, MBChB, DCH, DTM&amp;H, MPH,</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Gill, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Ward, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Graeme Meintjes, MBChB, FRCP, FCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Hatherill, MBChB, DCH, MRCP, FCPaed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorraine Swanepoel, B.Sc.Pharm, Hons. B.Pharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FAMCRU (Family Clinical Research with Ubuntu)</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanne Louw</last_name>
      <email>jeannes@sun.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Heather-Lee Fry, MBChB</last_name>
      <email>fry@sun.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Samantha Heather-Lee Fry, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emavundleni, Desmond Tutu Health Foundation</name>
      <address>
        <city>Cape Town</city>
        <zip>7750</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elaine Sebastian</last_name>
      <email>Elaine.Sebastian@hiv-research.org.za</email>
    </contact>
    <contact_backup>
      <last_name>Edith Kibiribiri</last_name>
      <email>Edith.Kibiribiri@hiv-research.org.za</email>
    </contact_backup>
    <investigator>
      <last_name>Llewellyn Fleurs, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda-Gail Bekker, MBChB, DTM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chatsworth, HIV Prevention Research Unit, South African Medical Research Council</name>
      <address>
        <city>Chatsworth</city>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dishiki Kalonji</last_name>
      <email>Dishiki.Kalonji@mrc.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Reshmi Dassaye</last_name>
      <email>ReshmiDassaye@mrc.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Reshmi Dassaye, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vuyiswa Kumalo, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isipingo, HIV Prevention Research Unit, South African Medical Research Council</name>
      <address>
        <city>Durban</city>
        <zip>4133</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dishiki Kalonji</last_name>
      <email>Dishiki.Kalonji@mrc.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Reshmi Dassaye, MBChB</last_name>
      <email>ReshmiDassaye@mrc.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Reshmi Dassaye, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vuyiswa Kumalo, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurum Institute Tembisa</name>
      <address>
        <city>Tembisa</city>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yajna Duki</last_name>
      <email>YDuki@auruminstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Kathryn Mngadi, MBChB, MPhil</last_name>
      <email>KMngadi@auruminstitute.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kathryn Mngadi, MBChB, MPhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>W1W 7TY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levy Mwanawasa University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <zip>10101</zip>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laston Chikoya, BSc, MBChB, MMed, MD</last_name>
      <phone>+260977349415</phone>
      <email>chikoyal@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Bright Nsokolo, BScHB, MB ChB, MMED</last_name>
      <phone>+260977884895</phone>
      <email>b_nsokolo@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Izukanji Sikazwe, MBChB, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roma Chilengi, MBChB, MSc, ACCRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn Bolton, MBBCh, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chikumbutso Chipeta, BScHB, MB ChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bright Nsokolo, BScHB, MB ChB, MMED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lloyd Mulenga, BScHB, MBCHB, MScID, MMED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia [CIDRZ]</name>
      <address>
        <city>Lusaka</city>
        <zip>H8R9+9V</zip>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izukanji Sikazwe</last_name>
    </contact>
    <investigator>
      <last_name>Izukanji Sikazwe</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roma Chilengi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn Bolton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chikumbutso Chipeta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe Clinical Trials Research Centre</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nyaradzo Mavis Mgodi, MBChB, MMed</last_name>
      <phone>+263 772 264 616</phone>
      <email>nmgodi@uzchs-ctrc.org</email>
    </contact>
    <contact_backup>
      <last_name>Teaclar Gamuchirai Nematadzira, : MBChB, Msc</last_name>
      <email>tnematadzira@uzchs-ctrc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nyaradzo Mavis Mgodi, MBChB, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teaclar Gamuchirai Nematadzira, MBChB, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gift Tafadzwa Chareka, Bachelor of Pharm, MscClin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allen Taguma Matubu, Bachelor Lab Sciences</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ghana</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Uganda</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Michael Avidan</investigator_full_name>
    <investigator_title>Professor of Anesthesiology and Surgery</investigator_title>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <keyword>Health care workers</keyword>
  <keyword>M-M-R II ®</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the main publication may be shared, after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From 3 months after the last patient last visit onward.</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by a review committee identified for this purpose.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

